인히비케이즈 테라퓨틱스(IKT)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.30 (+0.00%), 시가총액 $221.81M.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration.
인히비케이즈 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
인히비케이즈 테라퓨틱스의 현재 주가는 $2.30 (+0.00%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
인히비케이즈 테라퓨틱스의 시가총액은 약 $221.81M입니다.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary…